Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. filed a current report under Item 5.02 concerning executive appointments and related compensation changes. The earliest reported event occurred on October 4, 2022; the report was signed and dated October 6, 2022. Celularity is a Delaware biotechnology company whose Class A common stock trades on Nasdaq under “CELU.”
Key Financial and Compensation Information
- John R. Haines was appointed Senior Executive Vice President, General Manager and Chief Administrative Officer.
- Bradley Glover, Ph.D. was appointed Executive Vice President and Chief Operating Officer, succeeding Mr. Haines as principal operating officer.
- Mr. Haines’s annual base salary increased from $450,000 to $500,000.
- Dr. Glover’s annual base salary increased from $400,000 to $450,000.
- Dr. Glover’s target annual bonus had previously been increased from 25% to 45% of base salary in March 2022, subject to individual and company performance goals.
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating-period financial metrics.
Material Changes Versus the Prior Comparable Period
The filing reports immediate changes to senior management responsibilities. Mr. Haines moved into a broader senior executive, general management and administrative role, while Dr. Glover assumed the principal operating officer position. Their base salaries increased by approximately 11.1% each from the previously reported levels.
Outlook, Risks, Contingencies, and Unusual Items
- Dr. Glover’s employment agreement provides severance upon qualifying termination without cause or resignation for good reason, generally including 12 months of salary continuation, up to 12 months of COBRA coverage, a prorated bonus, and limited acceleration of time-based equity awards.
- If a qualifying termination occurs in connection with a change in control, the agreement provides 12 months of salary continuation, COBRA coverage, 100% of the target bonus for the termination year, and full acceleration of unvested equity awards.
- Severance is conditioned on execution of a release, return of company property and confidential information, compliance with post-termination obligations, and resignation from company positions.
- Dr. Glover’s agreement also includes a $66,000 retention payment, potential relocation reimbursement of up to $200,000, and limited expense reimbursement; the filing does not state whether any such amounts remain payable or were incurred as of the filing date.
- Change-in-control payments are subject to contractual tax-related limitations involving Section 4999 of the Internal Revenue Code.
- The executives are subject to standard indemnification arrangements, and Dr. Glover’s agreement includes confidentiality, invention, non-solicitation and non-competition provisions.
Important Facts for Investors to Verify
- Confirm the effective dates and scope of the new executive responsibilities.
- Review the complete employment agreement and severance provisions incorporated by reference into the filing.
- Assess the effect of the salary increases, bonus opportunities, retention arrangements and potential severance on future operating expenses and share-based compensation.
- Monitor whether the leadership changes affect Celularity’s operating execution, strategic priorities or development programs.
- Verify any future change-in-control, termination or equity-vesting events that could trigger material compensation obligations.